Enhanced Tumor Targeting and Antitumor Activity of Methylated β-Cyclodextrin-Threaded Polyrotaxanes by Conjugating Cyclic RGD Peptides
Biomolecules · 2024
DOI: 10.3390/biom14020223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Shunyao Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Biomaterials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai,…. Hauptthemen laut MEDLINE: Rotaxanes, beta-Cyclodextrins, Neoplasms, Peptides, Cyclic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Society for the Promotion of Science (JSPS) KAKENHI, TMDU wise program.
Abstract (Originalsprache)
We previously reported that acid-degradable methylated β-cyclodextrins (Me-β-CDs)-threaded polyrotaxanes (Me-PRXs) can induce autophagic cell death through endoplasmic reticulum (ER) stress-related autophagy, even in apoptosis-resistant cells. Hence, Me-PRXs show great potential as anticancer therapeutics. In this study, peptide-supermolecule conjugates were designed to achieve the targeted delivery of Me-PRX to malignant tumors. Arg-Gly-Asp peptides are well-known binding motifs of integrin αvβ3, which is overexpressed on angiogenic sites and many malignant tumors. The tumor-targeted cyclic Arg-Gly-Asp (cRGD) peptide was orthogonally post-modified to Me-PRX via click chemistry. Surface plasmon resonance (SPR) results indicated that cRGD-Me-PRX strongly binds to integrin αvβ3, whereas non-targeted cyclic Arg-Ala-Glu (cRGE) peptide conjugated to Me-PRX (cRGE-Me-PRX) failed to interact with integrins αvβ3. In vitro, cRGD-Me-PRX demonstrated enhanced cellular internalization and antitumor activity in 4T1 cells than that of unmodified Me-PRX and non-targeted cRGE-Me-PRX, due to its ability to recognize integrin αvβ3. Furthermore, cRGD-Me-PRX accumulated effectively in tumors, leading to antitumor effects, and exhibited excellent biocompatibility and safety in vivo. Therefore, cRGD conjugation to enhance selectivity for integrin αvβ3-positive cancer cells is a promising design strategy for Me-PRXs in antitumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Biomaterials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan.
ORCID-Profile: Atsushi Tamura, Nobuhiko Yui
Förderung
- Japan Society for the Promotion of Science
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- TMDU wise program
Zitieren
APA
Zhang, S., Tamura, A., & Yui, N. (2024). Enhanced Tumor Targeting and Antitumor Activity of Methylated β-Cyclodextrin-Threaded Polyrotaxanes by Conjugating Cyclic RGD Peptides. Biomolecules. https://doi.org/10.3390/biom14020223
Vancouver
Zhang S, Tamura A, Yui N. Enhanced Tumor Targeting and Antitumor Activity of Methylated β-Cyclodextrin-Threaded Polyrotaxanes by Conjugating Cyclic RGD Peptides. Biomolecules. 2024. doi:10.3390/biom14020223
BibTeX
@article{Zhang2024,
author = {Zhang, Shunyao and Tamura, Atsushi and Yui, Nobuhiko},
title = {Enhanced Tumor Targeting and Antitumor Activity of Methylated β-Cyclodextrin-Threaded Polyrotaxanes by Conjugating Cyclic RGD Peptides},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14020223}
}
EUVIMED